Clinical trials: Diuretics
Ascites
Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance
To investigate the safety and performance of the Automated Fluid Shunt in patients with ascites and diuretic resistance. Study Size and Duration The primary study population will include 40 patients enrolled and implanted with…
- Trial name
- PIONEER (NCT01030185)
- Testing
- NovaShunt's Automated Fluid Shunt implantation
- Where
- 9 sites in Belgium, Bulgaria and 2 more
- Volunteers
- 40 people
- Sponsor
- NovaShunt AG
Congestive Heart Failure
Hemodynamic Assessment in Acute Decompensated Heart Failure
This study will assess the ability of a novel optical measurement system to determine changes in the hemodynamic status of heart failure patients admitted to the hospital with a primary diagnosis of acute decompensated heart…
- Trial name
- NCT03535909
- Testing
- Noninvasive Hemodynamic Measurement System
- Where
- 2 sites in United States, Croatia
- Volunteers
- 5 people
- Sponsor
- Rodin Scientific LLC
Essential Arterial Hypertension
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on…
- Trial name
- ATHESA (NCT06608472)
- Testing
- N0877, Benicar HCT ® Tablets 40 mg/25 mg
- Sponsor
- Eurofarma Laboratorios S.A.
High Blood Pressure
A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.
This is an open-label, not controlled, sequential, dose escalation study of 16 weeks' duration. The study is composed of two periods: a 0-2 week optional wash-out period depending on previous antihypertensive treatment(s)…
- Trial name
- ANDROMEDA (NCT01056731)
- Testing
- Aliskiren and HCTZ
- Where
- 7 sites in Venezuela
- Volunteers
- 253 people
- Sponsor
- Novartis
Hypertension
Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension
The purpose of the study is to test the efficacy and safety of the combination of Calcium Channel Blockers (CCBs)(of the dihydropyridine class) or Diuretics (of the thiazide class) and olmesartan medoxomil in essential…
- Trial name
- NCT00858702
- Testing
- olmesartan medoxomil and a CCB, olmesartan medoxomil and a diuretic
- Where
- Japan
- Volunteers
- 105 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Heart Failure
Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure
The INTERVENE-HF study is a prospective, non-randomized, multi-center (US only), investigational, feasibility study. The purpose of this study is to characterize safety of managing heart failure patients with integrated device…
- Trial name
- NCT02698241
- Testing
- Diagnostic & Medication Management
- Where
- 8 sites in United States
- Volunteers
- 79 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Edema Secondary, Edema Leg
A Dose-finding Study of JMKX003142 in Treatment of Renal Edema
To evaluate the safety,efficacy, and pharmacokinetic characteristics of JMKX003142 administered randomly, double-blind, placebo-controlled study in Chinese renal edema patients with inadequate response to conventional diuretic…
- Trial name
- NCT06670534
- Testing
- JMKX003142 tablets
- Where
- 2 sites in China
- Volunteers
- 133 people
- Sponsor
- Jemincare
Essential Arterial Hypertension
Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension
Phase IIIb, randomized, double-blind, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination of losartan / chlorthalidone compared with losartan / hydrochlorothiazide in the treatment of…
- Trial name
- NCT04927299
- Testing
- Losartan/Chlorthalidone in fixed dose, Losartan + hydrochlorothiazide in fixed dose
- Where
- Mexico
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Uncontrolled Hypertension
A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.
This is a Phase IIIb, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of baxdrostat 2mg versus placebo, administered QD orally, on the reduction of ambulatory 24-hour average…
- Trial name
- BaxNoD (NCT07686120)
- Testing
- baxdrostat 2mg
- Where
- 51 sites in China
- Volunteers
- 286 people
- Sponsor
- AstraZeneca
Nocturia
Dose Range Finding Study of Fedovapagon in Men With Nocturia
The purpose of this study is to determine the dose level(s) of fedovapagon which result in a decrease in the mean nocturnal void frequency.
- Trial name
- NCT01656239
- Testing
- fedovapagon 1 mg, fedovapagon 2 mg, fedovapagon 4 mg
- Where
- 56 sites in United States
- Volunteers
- 358 people
- Sponsor
- Vantia Ltd
The Elderly (≥ 70 Years) With Essential Hypertension
Fimasartan in the Senior Subjects
The objective of this study is to confirm the noninferiority of the blood pressure lowering effect of fimasartan and evaluate its safety compared to perindopril in the elderly with essential hypertension.
- Trial name
- FITNESS (NCT03246555)
- Testing
- Fimasartan or Fimasartan/Hydrochlorothiazide, Perindopril or Perindopril/Indapamide
- Where
- South Korea
- Volunteers
- 241 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Heart Failure
NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure
NATRIUM-HF is a multicenter, non-randomized, pre-post intervention study designed to assess renal response to intravascular fluid expansion and diuretics after sacubitril/valsartan (Entresto®) in euvolemic heart failure patients…
- Trial name
- NATRIUM-HF (NCT04235062)
- Testing
- Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution, Intravenous Bolus Furosemide
- Where
- 13 sites in Armenia, Bosnia and Herzegovina and 1 more
- Volunteers
- 229 people
- Sponsor
- Momentum Research, Inc.
Congestive Heart Failure
Ultrafiltration Versus Intravenous (IV) Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure: (UNLOAD)
The purpose of this study is to compare patients who are suffering from heart failure and who are fluid overloaded to determine if ultrafiltration (UF) can remove more of the extra fluid as measured by weight loss while in the…
- Trial name
- NCT00124137
- Testing
- Aquadex system, IV diuretic
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Nuwellis, Inc.
Cardiac Edema
A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)
To investigate the plasma drug level, efficacy, and safety of 7-day repeated oral administration of OPC-41061 at 15 mg/day (treatment period 1) and subsequent 7-day repeated administration of OPC-41061 at 15 mg/day or 30 mg/day…
- Trial name
- NCT00544869
- Testing
- OPC-41061 （Tolvaptan)
- Where
- 6 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Hypertension, Blood Pressure, High
Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension
The purpose of this study is to determine if there is greater blood pressure reduction using ramipril or hydrochlorothiazide alone or ramipril and hydrochlorothiazide together.
- Trial name
- NCT00355589
- Testing
- Ramipril and hydrochlorothiazide
- Where
- 60 sites in United States
- Sponsor
- Pfizer
Heart Failure, Congestive, Renal Insufficiency
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
- Trial name
- NCT00159614
- Testing
- KW-3902IV
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acute Decompensated Heart Failure
DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
The study objective is to observe and measure clinical outcomes, urine output, and safety events occurring during standard medical treatment of ADHF patients deemed to have insufficient diuretic response.
- Trial name
- NCT04877652
- Testing
- Standard of care
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Revamp Medical Ltd.
Hypertension
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the U.S., which means that a doctor cannot…
- Trial name
- Darusentan (NCT00353574)
- Testing
- Darusentan
- Where
- 75 sites in United States, Argentina and 6 more
- Volunteers
- 282 people
- Sponsor
- Gilead Sciences
Hypertension
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
This is a double-blind, active-controlled, long-term study of a new experimental drug called darusentan. Darusentan in not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor…
- Trial name
- Darusentan (NCT00389675)
- Testing
- Darusentan, Guanfacine
- Where
- 99 sites in United States, Argentina and 2 more
- Volunteers
- 661 people
- Sponsor
- Gilead Sciences
Acute Decompensated Heart Failure
DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics
The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response.
- Trial name
- NCT05876078
- Testing
- Doraya catheter
- Where
- 10 sites in Germany, Italy and 3 more
- Volunteers
- 25 people
- Sponsor
- Revamp Medical Ltd.